NRXP NRX Pharmaceuticals, Inc.

XNAS 2.59 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

NRXP $2.59 —
Key stats
$2.59
52-Week Range
$1.62 – $5.05
YTD
-1.15%
IV Rank (30D)
64.25
Straddle Price
$0.85
P/C Vol Ratio
0.09
Market Cap
$0.1B
Open
$2.86
Day Range
$2.56 – $2.88
Volume
1,267,725
Prev Close
$2.80
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY1.02
Cost of Equity (CAPM)10.74% (VRP-adj)
WACC10.79%
Volatility Risk Premium+121.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)13811.8%
Book / Price-0.2%
Gross Margin (TTM)46.6%
FCF Margin (TTM)-609.0%
Quality Score2/6 — normal (10y DCF)
SMA 50$2.76 (Market Anchor value)
SMA 20 / Bollinger Mid$2.42
Bollinger Width / SMA2030.2% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABBV, ANRO, ATAI, CMPS, DFTX, HELP, NBIX, RLMD
Blended Fair Value
—
Deviation
—
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0% median 4.2× · 5 peers
Peer P/S n/a 0%
Market Anchor (SMA50) $2.76 0% stability 0% (BB-width)
Options Expected (B-L 30d) $2.71 0% 5 strikes · skew +0.04
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
29
List Date
2021-05-25
CIK
0001719406
Last Earnings
Aug 17 after close · +0.3% vs ±40.1% expected
Headquarters
Wilmington, DE
Homepage
https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan---40.24%-3.31%-25.85%1.00%-19.85%-17.65%
Feb---7.43%-13.56%-3.99%-18.93%-13.49%-11.48%
Mar---13.43%-29.13%7.72%0.99%18.01%-3.17%
Apr---35.54%-6.62%-50.86%9.28%37.96%-9.16%
May-6.02%-63.91%22.57%74.77%26.92%43.04%16.23%
Jun-46.65%4.90%-33.77%-36.95%21.64%-11.47%-17.05%
Jul27.24%41.10%-21.68%-11.24%-14.06%-18.71%0.44%
Aug-3.09%-20.73%-26.10%-13.02%-10.42%7.41%-10.99%
Sep-42.06%11.29%-12.75%2.74%26.92%-15.12%-4.83%
Oct16.04%7.26%13.20%-14.91%-7.19%-20.35%-0.99%
Nov-32.59%54.84%12.60%-5.42%-14.04%29.03%*7.40%
Dec-19.53%-25.00%25.34%62.96%13.39%--11.43%
Total-77.45%-81.88%-63.77%-56.80%23.31%8.88%-41.29%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.43
SMA 50: $2.75
SMA 200: $2.98
Current: $2.58
EMA 12: $2.45
EMA 26: $2.52
MACD: -0.0701 | Signal: 0.0552
BEARISH
ADX (14): 31.26
TREND
+DI: 28.99
−DI: 20.49

Momentum Oscillators

RSI (14): 51.60
NEUTRAL
Stoch %K: 66.41
Stoch %D: 47.03
Williams %R: -38.46

Volume & Volatility

BB Upper: $2.80
BB Lower: $2.05
NEUTRAL
OBV: 37,936,601
Vol SMA 20: 1,850,830
Vol ROC: 50.82%
ATR: $0.23
True Range: $0.32
HV 20: 117.5%
HV 30: 102.6%
HV 60: 76.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written without NRXP’s Aug 17 earnings results, so it doesn’t reflect them.

LLM Stock Analysis Report

Executive Summary Overall Assessment: BEARISH (Confidence Level: 7/10) Key Drivers: High volatility, negative recent news sentiment, technical breakdown Primary Risks: High risk due to beta >1.5 and high volatility Investment Thesis: NRXP's stock price is expected to decline in the short-term due to negative recent news sentiment and technical signals.

Recent News Sentiment Impact: The recent news headlines have been mixed, but the overall sentiment has been slightly negative. This has contributed to the bearish assessment.

Technical Analysis Trend Direction:

  • Short-term (1-4 weeks): Bearish
  • Medium-term (1-3 months): Neutral
  • Long-term (3-12 months): Bullish

Support/Resistance Levels: Key levels include $2.73 (lower Bollinger Band), $3.43 (current price), and $4.13 (upper Bollinger Band).

Momentum Signals:

  • RSI interpretation: Overbought (>70) at 46.83, indicating a potential sell signal.
  • MACD signal: Bearish due to the MACD histogram being below the zero line.
  • Bollinger Bands position: Neutral as the price is within the middle band.

Volume Analysis: Volume has been declining recently, which may indicate institutional disinterest and further selling pressure.

News & Sentiment Analysis Recent Headlines Summary: The news headlines have been mixed, but the overall sentiment has been slightly negative. The article about NRXP's public offering of common stock was neutral, while the articles discussing the company's financial results and appointments were positive. However, the recent decline in stock price due to earnings misses has contributed to a bearish sentiment.

Sentiment Assessment: Slightly Negative

Catalyst Identification: Upcoming earnings reports and product launches may impact the stock price.

Market Narrative: The technical signals are currently more bearish than the news sentiment, which may indicate a potential short-term decline in the stock price.

Risk & Volatility Assessment Beta Interpretation: High risk relative to the market (beta >1.5).

Volatility Regime: Current volatility is high compared to historical levels.

Options Market Signals:

  • IV rank: 41.0% (Medium)
  • Put/call ratios: Bearish sentiment
  • Unusual activity: High call volume and open interest

Downside Protection: Support levels include $2.73 (lower Bollinger Band) and $3.43 (current price).

Market Context & Positioning Sector Performance: Biotech sector has been strong recently, which may indicate that NRXP's stock price is due for a rebound.

Institutional Activity: Volume patterns suggest institutional disinterest and further selling pressure.

Correlation Analysis: The stock moves relatively strongly with the market (R-squared = 0.30).

Relative Valuation: The stock is trading within its normal range, but the recent decline may indicate that it's undervalued.

Key Levels & Action Items Critical Price Levels:

  • Support: $2.73 (lower Bollinger Band), $3.43 (current price)
  • Resistance: $4.13 (upper Bollinger Band)

Breakout/Breakdown Levels:

  • Breakout level: $4.13 (upper Bollinger Band)
  • Breakdown level: $2.73 (lower Bollinger Band)

Time-Sensitive Catalysts:

  • Upcoming earnings reports and product launches

Risk Management:

  • Stop-loss levels: Consider placing a stop-loss order around the support level ($2.73 or $3.43)
  • Position sizing considerations: Reduce position size due to high risk and volatility.

By analyzing the data, I have concluded that NRXP's stock price is expected to decline in the short-term due to negative recent news sentiment and technical signals. The company's high beta and volatility also contribute to its high risk profile. However, the biotech sector has been strong recently, which may indicate that NRXP's stock price is due for a rebound.

Generated
Earnings History
8 of 8 under expected move
Avg Expected Move
163.14%
Avg Actual Move
4.25%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-03-31 After-Close 32.62% 5.57% 0.17x Within
2023-11-14 After-Close 660.61% 7.14% 0.01x Within
2024-08-15 Pre-Market 268.82% 6.45% 0.02x Within
2024-11-15 Pre-Market 211.21% 2.59% 0.01x Within
2025-03-21 After-Close 19.23% 0.48% 0.02x Within
2025-05-21 After-Close 40.87% 2.28% 0.06x Within
2025-08-18 After-Close 31.70% 9.24% 0.29x Within
2026-08-17 After-Close 40.09% 0.29% 0.01x Within

Earnings calendar: this week’s reports with expected vs actual moves →

NRXP Options Activity & IV Rank

NRXP IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 190.0%
7-DTE IV: —
Expected Move: $0.85
7-DTE Move: $0.82
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 1,951
Put Volume: 179
P/C Volume: 0.092
BULLISH
Call OI: 20,623
Put OI: 401
P/C OI: 0.019
Total OI: 21,024

ATM Options Pricing

ATM Call: $0.40
ATM Put: $0.45
Call %: 15.4%
Put %: 17.4%

Chain Summary

Chain Volume: 2,130
Chain OI: 21,024
Last Updated: 11/19/2026

NRXP Implied Volatility

30-day IV
190.0%
Nov 19
IV rank
64Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much NRXP actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 56th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
56%
vs own history
GEX tilt
+0.84
OI-weighted, today
Vanna tilt
+0.88
δ-sensitivity to IV
Charm tilt
-0.90
δ-decay vs time
Vanna tilt +0.88: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.90: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 3k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 241.8% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)64.2MediumNov 19

Embed NRXP IV rank

NRXP's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$0.85Nov 19
Beta Analysis

Risk Metrics

Beta: 2.1217
Alpha: 33.84%
Correlation: 0.3319
R-Squared: 11.0%
Stock Volatility: 88.0%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NRXP
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$2.8M
0.00%
#2581 of 6285new13F
Millennium Management Hedge fund
Izzy Englander
$50K
0.00%
#3672 of 3716new13F
Renaissance Technologies Hedge fund
Jim Simons
$36K
0.00%
#3103 of 3151-68.1%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

NRXP Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 30,309,294 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

48 filers13,096,086 shares$46.19M value43.21% of float
# Filer Shares Value % of Total % of Float Period
1 B Group, Inc. 4,091,767 $16.74M 36.23% 13.50% 2026-06-30
2 Vanguard Capital Management LLC 1,789,291 $5.22M 11.31% 5.90% 2026-09-30
3 Ameriprise Financial, Inc. Custodian 928,728 $3.80M 8.22% 3.06% 2026-06-30
4 Balyasny Asset Management L.P. 893,864 $3.66M 7.91% 2.95% 2026-06-30
5 Marshall Wace, LLP Custodian 995,172 $2.91M 6.29% 3.28% 2026-09-30
6 Citadel Advisors LLC Custodian 680,043 $2.78M 6.02% 2.24% 2026-06-30
7 AdvisorShares Investments LLC 805,066 $2.35M 5.09% 2.66% 2026-09-30
8 COMMONWEALTH EQUITY SERVICES, LLC 590,768 $1.73M 3.73% 1.95% 2026-09-30
9 Geode Capital Management, LLC Custodian 446,457 $1.30M 2.82% 1.47% 2026-09-30
10 UBS Group AG Custodian 379,191 $1.11M 2.40% 1.25% 2026-09-30
11 Vanguard Fiduciary Trust Co 259,798 $758.61K 1.64% 0.86% 2026-09-30
12 BlackRock, Inc. Custodian 222,960 $651.04K 1.41% 0.74% 2026-09-30
13 State Street Corp 125,384 $366.12K 0.79% 0.41% 2026-09-30
14 Prime Capital Investment Advisors, LLC 124,631 $363.92K 0.79% 0.41% 2026-09-30
15 Bleakley Financial Group, LLC 117,216 $342.27K 0.74% 0.39% 2026-09-30
16 Morgan Stanley Custodian 102,207 $298.44K 0.65% 0.34% 2026-09-30
17 Northern Trust Corp Custodian 62,951 $257.47K 0.56% 0.21% 2026-06-30
18 One Wealth Management Investment & Advisory Services, LLC 43,309 $177.13K 0.38% 0.14% 2026-06-30
19 Chicago Partners Investment Group LLC 47,542 $118.38K 0.26% 0.16% 2026-09-30
20 Qube Research & Technologies Ltd 39,204 $114.48K 0.25% 0.13% 2026-09-30
21 Two Sigma Investments, LP Custodian 26,429 $108.09K 0.23% 0.09% 2026-06-30
22 Jane Street Group, LLC Custodian 36,293 $105.98K 0.23% 0.12% 2026-09-30
23 Global Retirement Partners, LLC 30,400 $88.77K 0.19% 0.10% 2026-09-30
24 GROUP ONE TRADING LLC Custodian 30,143 $88.02K 0.19% 0.10% 2026-09-30
25 ExodusPoint Capital Management, LP 19,308 $78.97K 0.17% 0.06% 2026-06-30
3 filers$1.89M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $927.61K 49.11% 2026-06-30
2 Citadel Advisors LLC Custodian $916.98K 48.54% 2026-06-30
3 Jane Street Group, LLC Custodian $44.38K 2.35% 2026-09-30
3 filers$359.79K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $215.54K 59.91% 2026-06-30
2 Citadel Advisors LLC Custodian $109.20K 30.35% 2026-06-30
3 Jane Street Group, LLC Custodian $35.04K 9.74% 2026-09-30

NRXP Insider Trading (Form 4)

Latest: 2026-11-04
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-04 Jonathan C Javitt CEO and Chairman Grant (A) +150,000 RSU — EDGAR
2026-11-04 Michael S Abrams Chief Financial Officer Grant (A) +75,000 RSU — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

NRXP Board & Officers

As of SEC filings through Nov 4, 2026

Directors 5

Officers 3

10% owners 2

  • B Group, Inc. (entity) · since Aug 18, 2025
  • Jonathan C Javitt · since May 24, 2021
Changes in the last 10 years (58)
Jan 27, 2026Joseph Michael Casper became Chief Operating Officer
Aug 18, 2025B Group, Inc. became a 10% owner
Jan 7, 2025The company announced the departure of Janet Rehnquist from the board in an SEC filing
Dec 18, 2024Jonathan C Javitt listed as Chairman and Chief Scientist (previously Chief Scientist) in SEC filings
Nov 18, 2024The company announced the departure of Richard Clavano Narido as Interim CFO in an SEC filing
Nov 18, 2024Michael S Abrams became Chief Financial Officer
Jun 13, 2024Dennis McBride became a director
Dec 28, 2023Janet Rehnquist became a director
Sep 13, 2023Richard Clavano Narido became Interim CFO
Sep 11, 2023The company announced the departure of Seth Van Voorhees as Chief Financial Officer in an SEC filing
Aug 23, 2023Jonathan C Javitt first listed as Chief Scientist in an SEC filing
Dec 9, 2022Jonathan C Javitt no longer listed as Chief Scientist in SEC filings
Jul 12, 2022Stephen H Willard became a director
Jul 12, 2022Stephen H Willard became Chief Executive Officer
Jun 13, 2022Seth Van Voorhees became Chief Financial Officer
Jun 2, 2022Jonathan C Javitt listed as Chief Scientist (previously Chief Executive Officer) in SEC filings
May 19, 2022The company announced the departure of Ira S Strassberg as Chief Financial Officer in an SEC filing
May 19, 2022The company announced the departure of Alessandra Daigneault as General Counsel & Secretary in an SEC filing
Mar 15, 2022Ira S Strassberg became Chief Financial Officer
May 26, 2021Herbert Raymond McMaster became a director
Not reported recently (16)
  • Aaron Gorovitz · Last reported as a director in an SEC filing dated Sep 11, 2023
  • Stephen H Willard · Last reported as a director in an SEC filing dated Dec 19, 2022
  • Daniel C. Javitt · Last reported as a 10% owner in an SEC filing dated Dec 1, 2022
  • Sharon Glied · Last reported as a director in an SEC filing dated Nov 22, 2022
  • Robert Besthof · Last reported as Chief Comm. & Patient Officer in an SEC filing dated Mar 10, 2022
  • Herbert Raymond McMaster · Last reported as a director in an SEC filing dated Nov 2, 2021
  • Daniel Troy · Last reported as a director in an SEC filing dated Jun 10, 2021
  • William Fricker · Last reported as CFO & Treasurer in an SEC filing dated Jun 10, 2021
  • Steven Levine · Last reported as a 10% owner in an SEC filing dated Nov 26, 2018
  • David M Nussbaum · Last reported as a 10% owner in an SEC filing dated Nov 26, 2018
  • Bennett Kim · Last reported as Chief Invt. Ofc. & Corp. Sec. in an SEC filing dated Dec 4, 2017
  • Lori Wittman · Last reported as a director in an SEC filing dated Dec 4, 2017
  • Stuart F. Koenig · Last reported as a director in an SEC filing dated Dec 4, 2017
  • Albert G. Rex · Last reported as a director in an SEC filing dated Dec 4, 2017
  • Michael Fong · Last reported as a director in an SEC filing dated Dec 4, 2017
  • Richard Birdoff · Last reported as a director in an SEC filing dated Dec 4, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-16
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-02 Regulation FD disclosure EDGAR
2026-10-16 Other events EDGAR
2026-10-05 Material agreement EDGAR
2026-09-16 Other events EDGAR
2026-09-14 Regulation FD disclosure EDGAR
2026-08-17 Earnings results EDGAR
2026-08-07 Regulation FD disclosure EDGAR
2026-07-22 Other events EDGAR
2026-06-04 Material agreement · Other events EDGAR
2026-06-02 Other events EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-16 0001437749-26-037198 EDGAR
2026-08-14 0001437749-26-028027 EDGAR
ETF Holders
4 ETFs hold NRXP
4 shown · $6.32M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 PSIL AdvisorShares Psychedelics ETF Nport 6.07% $2.7M — 2026-06-30
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $2.3M — 2026-10-31
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.1M — 2026-10-31
4 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.02% $252,561 $1.2B 2026-11-17
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.74
TTM Revenue
$3.39M
TTM Net Income
$-23.48M
TTM Op. Cash Flow
$-19.77M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$1.10M$-16.52M$-0.44$-8.88M
Q1 '262026-03-31$1.07M$-1.43M$-0.04$-4.29M
Q4 '252025-12-31$983.00K$360.00K$0.01$-3.71M
Q3 '252025-09-30$242.00K$-5.89M$-0.27$-2.89M
Q2 '252025-06-30—$-17.58M$-0.98$-4.03M
Q1 '252025-03-31—$-5.51M$-0.34$-3.48M
Q4 '242024-12-31—$-9.08M$-0.77$-2.10M
Q3 '242024-09-30—$-1.62M$-0.15$-2.31M
Q2 '242024-06-30—$-7.90M$-0.75$-2.56M
Q1 '242024-03-31—$-6.53M$-0.74$-3.67M
Q4 '232023-12-31—$-4.34M$-0.50$-3.19M
Q3 '232023-09-30—$-6.06M$-0.74$-4.56M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-14
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
25.00
EV/EBITDA
—
EV/Sales
17.14
ROE
—
ROA
-68.7%
Div Yield
0.00%
FCF Yield
-23.30%
Debt/Equity
—
Current Ratio
—
Market Cap
$84.87M
as of 2026-11-18

NRXP vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
ABBV ABBVIE INC. $505.6B 48.7 +10.7% +23.3% 49
NBIX Neurocrine Biosciences Inc $16.5B 23.4 +38.0% +12.3% 39
DFTX Definium Therapeutics, Inc. Common Share $4.0B — — +92.7% 27
ATAI AtaiBeckley Inc. Common Stock $2.7B — +811.8% +89.9% —
CMPS COMPASS Pathways Plc American Depository $1.2B — — +31.8% 34
ANRO Alto Neuroscience Inc. $1.0B — — +59.7% 50
HELP Helus Pharma Inc. Common Stock $550M — — −12.9% 37
RLMD Relmada Therapeutics, Inc. Common Stock $305M — — −28.7% 18
NRXP NRX Pharmaceuticals, Inc. Common Stock $124M — — −1.5% 64
Peer median $1.9B 36.0 +38.0% +27.5% 37

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
10.46M
SI % of Float
30.76%
Days to Cover
4.56
Short Vol Ratio
47.8%
Free Float
34.01M
Float %
93.9%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-08-14